NewcelX Will Attend Breakthrough T1D Congress
Management will highlight the NCEL-101 therapy development at the Philadelphia event from October 9-11, 2026.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you feel optimistic that new stem-cell-derived therapies will soon provide functional cures for diabetes?
NewcelX management will attend the Breakthrough T1D Clinical & Research Congress held in Philadelphia from October 9-11, 2026. The company is currently advancing IND-enabling activities for its lead therapy, NCEL-101, designed to restore insulin production in patients.
Why it matters
The company aims to progress its treatment through the regulatory process following recent guidance from federal authorities. The upcoming congress serves as a platform for NewcelX to engage with the clinical and research community regarding their development strategy.
NewcelX is developing NCEL-101 as a Phase 1/2a clinical candidate that integrates stem-cell-derived pancreatic islet cells with the anti-CD40L antibody tegoprubart. The development remains subject to completing mandatory IND-enabling requirements.
The players
NewcelX
This is a publicly traded biotechnology company based in Zurich that focuses on developing therapies for Type 1 Diabetes.
Food and Drug Administration
This federal agency is responsible for regulating the development and approval of new pharmaceutical therapies in the United States.
Breakthrough T1D
This organization hosts clinical and research congresses to foster collaboration in the effort to treat and cure Type 1 Diabetes.
The details
NewcelX, which trades on the Nasdaq under the ticker NCEL, is working on preclinical, manufacturing, and regulatory milestones to support an upcoming IND submission. Management will use the congress to interface with investors, researchers, and potential clinical partners.
Timeline
In July 2026, the company held a Type B Pre-IND meeting with the FDA.
On September 28, 2026, NewcelX announced its planned attendance at the congress.
Management will attend the Breakthrough T1D Congress from October 9-11, 2026.
The Big Picture
The Breakthrough T1D Clinical & Research Congress serves as a critical junction for firms developing novel endocrine therapies to align with the scientific community. NewcelX's participation follows the established pattern of emerging biotech firms using this congress to showcase progress toward clinical trials.
While the therapy is not currently available for patient use, the advancement toward Phase 1/2a trials represents a potential future treatment path for managing Type 1 Diabetes. Patients should monitor clinical registry updates for future information regarding trial enrollment eligibility.
The takeaway
The progression of NCEL-101 through regulatory milestones reflects the ongoing efforts to develop long-term insulin-restoration solutions. Investors and patients should track the company's progress regarding its upcoming FDA application as a primary indicator of development success.
Further reading
For broader insights on therapeutic advancements, see the Diabetes section.
Live Poll
Do you feel optimistic that new stem-cell-derived therapies will soon provide functional cures for diabetes?
